A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ALXN2050, A COMPLEMENT FACTOR D INHIBITOR, IN IMMUNOGLOBULIN A NEPHROPATHY OR PROLIFERATIVE LUPUS NEPHRITIS (LN)
Back
Abstract Number
WCN23-0141
Categories
AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Clinical Glomerulonephritis
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF ALXN2050, A COMPLEMENT FACTOR D INHIBITOR, IN IMMUNOGLOBULIN A NEPHROPATHY OR PROLIFERATIVE LUPUS NEPHRITIS (LN)
Co-authors
Bapat, A.(1)*;Garlo, K.(1);Rice, K.(1);Najafian, N.(1)
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)Alexion Astrazeneca Rare Disease, Research And Development-Clinical Development, Boston, United States
E-Poster
https://storage.unitedwebnetwork.com/files/1/b3c97f4bea84e31d766744c6a2806cea.pdf
Audio File
https://storage.unitedwebnetwork.com/files/1041/f401e5803717f2f55f2de7592879a7f4.mp3
if any